Glurenor

Glurenor is a prescription medication that contains the active ingredient gliquidone, a sulfonylurea oral antidiabetic agent. It is marketed in the European Union and is supplied in tablet form, although specific strength information is not publicly disclosed. Gliquidone works by stimulating insulin release from pancreatic beta‑cells, helping to lower blood glucose levels in adults with type 2 diabetes mellitus. The product requires a health‑care provider’s prescription.

Glurenor is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient.

- As monotherapy for adults with type 2 diabetes inadequately controlled by lifestyle measures. - In combination with metformin when additional glucose lowering is required. - As part of a regimen that includes other oral hypoglycemics, such as thiazolidinediones. - To improve glycemic control in patients who are not candidates for insulin therapy. - For use in patients with stable renal function and no contraindicating conditions.

The safety profile of Glurenor reflects the typical effects observed with sulfonylurea agents, ranging from mild, frequently reported events to rare but serious reactions.

Common: - Mild hypoglycemia, especially if meals are missed or delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Headache or dizziness. - Weight gain due to increased insulin activity. - Transient flushing or warmth sensation.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including rash, pruritus, or angio‑edema. - Hepatotoxicity manifested by elevated liver enzymes. - Blood dyscrasias such as leukopenia or thrombocytopenia.

When prescribing Glurenor, clinicians should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

- Assess renal and hepatic function before initiation and periodically during therapy. - Use caution in elderly patients due to heightened susceptibility to hypoglycemia. - Avoid use in individuals with known sulfonylurea hypersensitivity. - Monitor blood glucose regularly to detect both hyper‑ and hypoglycemic episodes. - Adjust dose or discontinue if persistent low blood glucose occurs. - Counsel patients on recognizing signs of hypoglycemia and the importance of consistent meals.

Glurenor may interact with other medicines, affecting blood glucose levels or increasing the risk of side effects.

Avoid: - Concurrent use with other sulfonylureas or insulin that can cause additive hypoglycemia. - Co‑administration with potent CYP2C9 inhibitors (e.g., fluconazole) that may raise gliquidone concentrations.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may impair glucose tolerance. - Anticoagulants such as warfarin, requiring closer INR monitoring. - Alcohol, which can potentiate hypoglycemic effects, especially when consumed with meals.